CL2020002564A1 - Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso - Google Patents

Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso

Info

Publication number
CL2020002564A1
CL2020002564A1 CL2020002564A CL2020002564A CL2020002564A1 CL 2020002564 A1 CL2020002564 A1 CL 2020002564A1 CL 2020002564 A CL2020002564 A CL 2020002564A CL 2020002564 A CL2020002564 A CL 2020002564A CL 2020002564 A1 CL2020002564 A1 CL 2020002564A1
Authority
CL
Chile
Prior art keywords
compounds
methods
differentiation factor
agonist compounds
growth differentiation
Prior art date
Application number
CL2020002564A
Other languages
English (en)
Inventor
Victor H Obungu
Malgorzata Donata Gonciarz
Richard Todd Pickard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2020002564A1 publication Critical patent/CL2020002564A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en la presente compuestos que inducen pérdida de peso y que tratan la diabetes, dislipidemia, NASH y/u obesidad. También se proporcionan composiciones farmacéuticas que contienen dichos compuestos y usos terapéuticos de tales compuestos y composiciones, en donde dichos compuestos actúan como agonistas de GDF15 con un tiempo de acción prolongado y otras propiedades ventajosas.
CL2020002564A 2018-04-06 2020-10-02 Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso CL2020002564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862653759P 2018-04-06 2018-04-06

Publications (1)

Publication Number Publication Date
CL2020002564A1 true CL2020002564A1 (es) 2021-01-29

Family

ID=66630339

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002564A CL2020002564A1 (es) 2018-04-06 2020-10-02 Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso

Country Status (29)

Country Link
US (1) US11104711B2 (es)
EP (1) EP3774860B1 (es)
JP (1) JP7064618B2 (es)
KR (1) KR102501922B1 (es)
CN (1) CN112004821B (es)
AR (1) AR115021A1 (es)
AU (1) AU2019248535B2 (es)
BR (1) BR112020017256A2 (es)
CA (1) CA3096375C (es)
CL (1) CL2020002564A1 (es)
CO (1) CO2020012403A2 (es)
CR (1) CR20200454A (es)
DO (1) DOP2020000157A (es)
EA (1) EA202092084A1 (es)
EC (1) ECSP20062930A (es)
ES (1) ES2937049T3 (es)
IL (1) IL276980A (es)
JO (1) JOP20200252B1 (es)
MA (1) MA52228A (es)
MX (1) MX2020010370A (es)
MY (1) MY202810A (es)
PE (1) PE20212133A1 (es)
PH (1) PH12020551656A1 (es)
SA (1) SA520420287B1 (es)
SG (1) SG11202009853VA (es)
TW (1) TWI724392B (es)
UA (1) UA127545C2 (es)
WO (1) WO2019195091A1 (es)
ZA (1) ZA202005385B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CR20200510A (es) 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
KR20230078748A (ko) * 2020-10-02 2023-06-02 일라이 릴리 앤드 캄파니 항체 정제 공정에서의 숙주 세포 단백질 함량을 감소시키는 방법 및 감소된 숙주 세포 단백질 함량을 가지는 항체 조성물
US20240391971A1 (en) * 2021-08-24 2024-11-28 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
JP2025504612A (ja) 2021-12-31 2025-02-13 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｇｌｐ－１及びｇｄｆ１５の融合タンパク質並びにその使用
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US9221882B2 (en) * 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
ES2791183T3 (es) * 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
CA2919076C (en) 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
EP3701969A1 (en) * 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
EP3277304B1 (en) 2015-04-02 2021-08-04 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
WO2017147743A1 (zh) 2016-02-29 2017-09-08 华为技术有限公司 视频优化方法、用户设备和网络设备
CN108697795A (zh) 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
US20170299608A1 (en) 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
AU2019248535B2 (en) 2021-09-02
CN112004821A (zh) 2020-11-27
KR102501922B1 (ko) 2023-02-23
CA3096375A1 (en) 2019-10-10
CO2020012403A2 (es) 2020-10-30
TW201946661A (zh) 2019-12-16
PH12020551656A1 (en) 2021-07-26
US20190309033A1 (en) 2019-10-10
DOP2020000157A (es) 2020-09-15
JOP20200252B1 (ar) 2023-09-17
EA202092084A1 (ru) 2021-01-27
SG11202009853VA (en) 2020-11-27
MA52228A (fr) 2021-02-17
JOP20200252A1 (ar) 2020-10-04
CR20200454A (es) 2020-11-18
PE20212133A1 (es) 2021-11-05
EP3774860A1 (en) 2021-02-17
NZ767242A (en) 2024-07-05
BR112020017256A2 (pt) 2020-12-22
JP2021517584A (ja) 2021-07-26
WO2019195091A1 (en) 2019-10-10
CA3096375C (en) 2023-09-12
UA127545C2 (uk) 2023-10-04
SA520420287B1 (ar) 2024-03-17
ZA202005385B (en) 2022-09-28
EP3774860B1 (en) 2022-12-28
TWI724392B (zh) 2021-04-11
IL276980A (en) 2020-10-29
MX2020010370A (es) 2021-01-08
ES2937049T3 (es) 2023-03-23
JP7064618B2 (ja) 2022-05-10
KR20200128091A (ko) 2020-11-11
US11104711B2 (en) 2021-08-31
MY202810A (en) 2024-05-23
AR115021A1 (es) 2020-11-18
CN112004821B (zh) 2024-01-02
ECSP20062930A (es) 2020-11-30
AU2019248535A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
CL2020002564A1 (es) Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2019002464A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán.
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
CR20170108A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
CO2021006482A2 (es) Ureas cíclicas
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
CL2020001140A1 (es) Compuestos espirocíclicos como moduladores del receptor farnesoide x.
MX2021011008A (es) Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
EA201890800A1 (ru) Соединения и композиции для лечения глазных расстройств
MX2024013040A (es) Pirfenidona enriquecida con deuterio y metodos para su uso
SV2018005731A (es) Piperidinas sustituidas con halo como moduladores del receptor de orexina
CL2012000013A1 (es) Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer.
CR20210021A (es) Apirasas solubilizadas, métodos y usos
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX2022014899A (es) Variantes y composiciones del lfa3 y sus usos.
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.